Unique ID issued by UMIN | UMIN000015896 |
---|---|
Receipt number | R000018501 |
Scientific Title | Drug Use-results Surveillance of SOVRIAD capsules100mg. |
Date of disclosure of the study information | 2014/12/15 |
Last modified on | 2019/03/06 10:51:36 |
Drug Use-results Surveillance of SOVRIAD capsules100mg.
Drug Use-results Surveillance of SOVRIAD capsules100mg.
Drug Use-results Surveillance of SOVRIAD capsules100mg.
Drug Use-results Surveillance of SOVRIAD capsules100mg.
Japan |
chronic hepatitis C.
Hepato-biliary-pancreatic medicine |
Others
NO
To confirm the safety and efficacy of Sovriad Capsules in the patients with chronic hepatitis C.
Safety,Efficacy
Safety(Adverse Drug Reaction)
Effectiveness(SVR12,SVR24)
Observational
Not applicable |
Not applicable |
Male and Female
Patients with chronic hepatitis C who are treated with SOVRIAD capsules for the first time
NA
2200
1st name | |
Middle name | |
Last name | Toshiya Kato |
Janssen Phrmaceutical K.K.
Safety Risk Management Dept.
5-2,Nishi-Kanda 3-Chome, Chiyoda-ku, Tokyo
03-4411-5478
tkato1@ITS.JNJ.com
1st name | |
Middle name | |
Last name | Akiko Yamamoto |
Janssen Phrmaceutical K.K.
Safety Risk Management Dept.
5-2,Nishi-Kanda 3-Chome, Chiyoda-ku, Tokyo
03-4411-5173
ayamamot@its.jnj.com
Janssen Phrmaceutical K.K.
Janssen Phrmaceutical K.K.
Profit organization
NO
2014 | Year | 12 | Month | 15 | Day |
Unpublished
Open public recruiting
2013 | Year | 11 | Month | 07 | Day |
2013 | Year | 12 | Month | 18 | Day |
2017 | Year | 12 | Month | 31 | Day |
Prospectives study
2014 | Year | 12 | Month | 10 | Day |
2019 | Year | 03 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018501